Skip to main content

Advertisement

Fig. 3 | Respiratory Research

Fig. 3

From: Azithromycin and risk of COPD exacerbations in patients with and without Helicobacter pylori

Fig. 3

Serial change in blood biomarkers according to baseline H. pylori (HP) status and treatment. AZ, Azithromycin; PL, Placebo. The points and error bars indicate the means and standard errors of change in C-reactive protein (CRP) and soluble tumor necrosis factor-75 (sTNFR75) levels from baseline to 3, 12, and 13 months for each of the 4 groups. Paired t-tests were used to determine differences in biomarker concentrations between the three time points and baseline levels. * p < 0.05, ** p < 0.01. a CRP decreased significantly at 3 months in the HP-/AZ and AZ use group. After stopping AZ at 12 months, CRP returned to baseline levels at 13 months. b sTNFR75 levels decreased significantly at 3 months only in the HP+/AZ group and returned to baseline levels after stopping AZ

Back to article page